Alzheimer Gene Therapy LX1001 Demonstrates Dose|Dependent ...

Alzheimer Gene Therapy LX1001 Demonstrates Dose-Dependent ...

LX1001 gene therapy showed dose- and time-dependent increases in APOE2 expression in APOE4 homozygote Alzheimer's patients.

Lexeo Therapeutics Announces Positive Interim Data for LX1001 ...

... gene therapy candidate for the treatment of APOE4-homozygous Alzheimer's disease. Individuals homozygous for APOE4, an allele of the gene APOE ...

Lexeo Therapeutics' Gene Therapy LX1001 Increases APOE2 ...

Lexeo Therapeutics' LX1001, an investigational adeno-associated virus (AAV) vector-based gene therapy, has demonstrated a dose- and ...

Lexeo Therapeutics Announces Positive Interim Data for

Treatment with LX1001 led to dose-dependent increases in APOE2 protein expression and improvements in AD-associated tau biomarkers.

Gene Therapy for APOE4 Homozygous Alzheimer Disease

R. Nolan Townsend, Sandi See Tai, MD, and Kim G. Johnson, MD, discussed Lexeo Therapeutics' LX1001 gene therapy trial that demonstrated ...

Gene Therapy: Lexeo Therapeutics' LX1001 Shows Promise for ...

Lexeo Therapeutics reveals promising interim results for LX1001, a gene therapy aimed at APOE4-linked Alzheimer's, showcasing dose-dependent ...

NeurologyLive® on X: "LX1001 (Lexeo Therapeutics), an AAV ...

LX1001 (Lexeo Therapeutics), an AAV investigational gene therapy ... Alzheimer Gene Therapy LX1001 Demonstrates Dose-Dependent Increase in APOE2 ...

Lexeo showcases encouraging early data for Alzheimer's gene ...

... Alzheimer's disease gene therapy, dubbed LX1001, presented at the Cl ... Alzheimer's received LX1001 across four dose-escalating cohorts.

LX1001 | ALZFORUM

APOE gene isoforms strongly affect the risk of developing Alzheimer's disease. APOE4 raises the risk, APOE2 reduces it. APOE4 is associated with ...

Promising Innovative Gene Therapy for APOE4 Homozygous ...

... therapy trial that demonstrated promising safety and biomarker effects in patients with early-stage Alzheimer disease ... dose showed 32 ...

Lexeo Therapeutics Reports Positive Interim Data for LX1001 ...

Lexeo Therapeutics Reports Positive Interim Data for LX1001 Alzheimer's Gene Therapy at CTAD Conference. 1 November 2024. Lexeo Therapeutics, Inc.

Lexeo Therapeutics Announces Positive Interim Data for LX1001 ...

... LX1001, a gene therapy for APOE4-associated Alzheimer's disease. The therapy demonstrated dose-dependent increases in neuroprotective APOE2 ...

Lexeo Therapeutics Scores Positive Early Data for APOE4 ...

An Alzheimer's gene therapy for those with the APOE4 mutation, developed by Lexeo Therapeutics, shows promise at Phase I/II.

Lexeo Therapeutics announces positive results from Phase 1/2 ...

... LX1001 as a potential therapy for the more progressive course of Alzheimer's seen in APOE4 homozygotes. LX1001 is an AAVrh10-based gene therapy ...

AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy ...

Crossing a transgenic mouse model of AD that has high levels of human Aβ in the brain with human APOE targeted replacement mice demonstrated age-dependent and ...

Lexeo Therapeutics' APOE4-Associated Alzheimer's Trial Shows ...

Lexeo Therapeutics has announced promising interim results from its Phase I/II trial of LX1001, an innovative gene therapy targeting ...

Alzheimer Gene Therapy LX1001 Demonstrates Dose-Dependent ...

Alzheimer Gene Therapy LX1001 Demonstrates Dose-Dependent Increase in APOE2 Expression · Next PostGeneralized Myasthenia Gravis Classification and Treatment ...

Cell and Gene Therapy Shows Early Promise Against Alzheimer's ...

Longeveron and Lexeo Therapeutics are working on CGT therapies to treat Alzheimer's disease, but it's not clear whether they have a better chance of success ...

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 ...

The presentation will include new safety and biomarker data from four dose cohorts of LX1001, an AAVrh10-based gene therapy candidate.

Novel Gene Therapy Approach in ADDF-Funded Trial Reports ...

... LX1001, a unique treatment approach that targets the underlying genetics of Alzheimer's disease ... dose levels of LX1001 and assessing ...